Use of warfarin in the patient with cancer

Journal of Supportive Oncology

Volumn 5, Issue 3, 2007, Pages 131-136

  Pangilinan, Joanna Maudlin ^a   Pangilinan Jr , Percival H ^b   Worden, Francis P ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; DEXAMETHASONE; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; GRANISETRON; HEMOGLOBIN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN; LOPERAMIDE; LORAZEPAM; LOW MOLECULAR WEIGHT HEPARIN; PHYTOMENADIONE; PROCHLORPERAZINE; SALVIA MILTIORRHIZA EXTRACT; WARFARIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTICOAGULATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER STAGING; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; COLON CANCER; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HEART FUNCTION TEST; HEMOGLOBIN DETERMINATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE; LIVER FUNCTION TEST; LIVER METASTASIS; MOOD; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; PROTHROMBIN TIME; THROMBOCYTE COUNT; VITAMIN SUPPLEMENTATION;

ANALGESICS, NON-NARCOTIC; ANEMIA; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; NEOPLASMS; THROMBOCYTOPENIA; WARFARIN;

EID: 34249067669     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004;329:15-19. [15231615]
2. Fanikos J, Stapinski C, Koo S, Kucher N, Tsilimingras K, Goldhaber SZ. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol 2004;94:532-535.[15325949]
3. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995;74:1055-1058. [8560413]
4. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662. [9496982]
5. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400.[11560452]
6. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.[10963635]
7. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):204S-233S.[15383473]
8. Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 1997;78:785-790.[9268171]
9. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003;3:221-230. [15199454]
10. Eckhoff CD, Didomenico RJ, Shapiro NL. Initiating warfarin therapy: 5 mg versus 10 mg. Ann Pharmacother 2004;38:2115-2121.[15522981]
11. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.[12853587]
12. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):401S-428S.[15383479]
13. National Comprehensive Cancer Network Venous Thromboembolic Disease v.2.2006. Available at http://www.nccn.org/professionals/physician_gls/ PDF/vte.pdf. Accessed February 5, 2007.
14. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673-684.[16670137]
15. Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med 2003;70:361-371. [12701992]
16. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-1106.[15911722]
17. Demirkan K, Stephens MA, Newman KP, Self TH. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000;93:448-454. [10832939]
18. Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2005.
19. Severijnen R, Bayat N, Bakker H,Tolboom J, Bongaerts G. Enteral drug absorption in patients with short small bowel: a review. Clin Pharmacokinet 2004;43:951-962.[15530127]
20. Lonning PE, Kvinnsland S, Jahren G. Aminoglutethimide and warfarin: a new important drug interaction. Cancer Chemother Pharmacol 1984;12:10-12.[6690067]
21. Janney LM, Waterbury NV. Capecitabine-warfarin interaction. Ann Pharmacother 2005;39:1546-1551. [16014372]
22. Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005;23:4719-4725.[16034047]
23. Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction - a consecutive case series. Pharmacotherapy 1999;19:1445-1449. [10600095]
24. Davis DA, Fugate SE. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy. Pharmacotherapy 2005;25:442-447.[15843293]
25. Kinikar SA, Kolesar JM. Identification of a gemcitabine-warfarin interaction. Pharmacotherapy 1999;19:1331-1333.[10555940]
26. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin. Ann Oncol 2003;14:500. [12598362]
27. Casodex [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2003.
28. Flutamide (package insert]. Princeton, NJ: Sandoz Pharmaceuticals; 2005.
29. Nilandron [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2006.
30. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ 1989;298:93.[2493305]
31. Fareston [package insert]. Memphis, TN: GTx, Inc.; 2006.
32. Hansten PD, Horn JT, eds. Hansten and Horn's Drug Interactions, Analysis and Management. St Louis:Wolters Kluwer Health, Inc; 2006.
33. Tarceva [package insert]. Melville, NY: Genentech/ OSI Pharmaceuticals; 2004.
34. Onoda S, Mitsufuji H, Yanase N, et al. Drug interaction between gefitinib and warfarin. Jpn J Clin Oncol 2005;35:478-482.[16006576]
35. Nissenblatt MJ, Karp GI. Bleeding risk with trastuzumab (Herceptin) treatment JAMA 1999;282:2299-2301.[10612314]
36. Nexavar [package insert]. Leverkusen, Germany: Bayer Health Care AG; 2005.
37. Adachi Y, Yokoyama Y, Nanno T, Yamamoto T. Potentiation of warfarin by interferon. BMJ 1995;311:292. [7543311]
38. Wehbe TW, Warth JA. A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. Clin Pharmacot Ther 1996;59:360-362.[8653999]
39. Le AT, Hasson NK, Lum BL. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 1997;31:1006-1008.[9296241]
40. Magagnoli M, Masci G, Castagna L, et al. High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin. Br J Haematol 2005;129:709-710 [15916696]
41. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 1994;28:464-467. [8038468]
42. Hall G, Lind MJ, Huang M, et al. Intravenous infusions of ifosfamide/ mesna and perturbation of warfarin anticoagulant control. Postgrad Med J 1990;66:860-861. [2129174]
43. Tashima CK. Cyclophosphamide effect on coumarin anticoagulation. South Med J 1979;72:633-634. [441785]
44. Martin LA, Mehta SD. Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. Pharmacotherapy 2003;23:260-264. [12587816]
45. Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters - a reappraisal of the evidence. Br J Cancer 2006;94:189-194.[16404436]
46. Masci G, Magagnoli M, Zucali PA, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003;21:736-739.[12586814]
47. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol 2006;13:357-361. [16888441]
48. Emend [package insert]. Whitehouse Station, NJ: Merck and Company; 2005.
49. Camptosar [package insert]. New York, NY: Pfizer, Inc; 2005.
50. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-1347. [10658525]
51. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006;33:2-14.[16473642]
52. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006;33:50-67. [16473644]
53. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI,the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004;92:797-802.[15467911]
54. Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy 2003;23:109-112.[12523469]
55. Shek KL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. Pharmacotherapy 1999;19:1153-1158.[10512064]
56. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005;165:189-192.[15668365]
57. Rothschild BM. Hematologic perturbations associated with salicylate. Clin Pharmacol Ther 1979;26:145-152.[378508]
58. Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr Rev 1999;57:288-296.[10568341]
59. Molassiotis A, Fernandez-Ortega P, Pud D, et al. Complementary and alternative medicine use in colorectal cancer patients in seven European countries. Complement Ther Med 2005;13:251-257. [16338195]
60. Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 2005;130:777-780. [16115136]
61. US Food and Drug Administration. Overview of dietary supplements. Available at: http://www.cfsan.fda.gov/~dms/ds-oview.html. Accessed February 5, 2007.
62. Chan TY. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother 2001;35:501-504.[11302416]
63. Zhou S, Chan E, Pan SO, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St. John's wort. J Psychopharmacol 2004;18:262-276.[15260917]